AN INVESTIGATION INTO THE MECHANISMS OF THE CARDIOVASCULAR EFFECTS OF 5‐HYDROXYTRYPTAMINE IN CONSCIOUS NORMOTENSIVE AND DOCA‐SALT HYPERTENSIVE RATS

Journal of Autonomic Pharmacology

Volumn 6, Issue 3, 1986, Pages 219-228

  DALTON, D W ^a   FENIUK, W ^a   HUMPHREY, P P A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLSEROTONIN; 5 CARBAMOYLTRYPTAMINE; ALPHA METHYLSEROTONIN; ANGIOTENSIN; BEMESETRON; DEOXYCORTICOSTERONE ACETATE; ISOPRENALINE; KETANSERIN; METHYSERGIDE; METITEPINE; PHENTOLAMINE; SEROTONIN; SEROTONIN 3 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR SYSTEM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMPARISON; DRUG MECHANISM; DRUG RESPONSE; HEART; HEART RATE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; BLOOD PRESSURE; DESOXYCORTICOSTERONE; HEART RATE; HEMODYNAMICS; HYPERTENSION; MALE; RATS; SEROTONIN; SEROTONIN ANTAGONISTS; TROPANES;

EID: 0022448109     PISSN: 01441795     EISSN: 13652680     Source Type: Journal    
DOI: 10.1111/j.1474-8673.1986.tb00648.x     Document Type: Article

References (32)

1. Proposals for the classification and nomenclature of functional receptors for 5‐hydroxytryptamine
2. Vascular reactivity of isolated perfused kidneys from male and female spontaneously hypertensive rats
3. 5‐Carboxamidotryptamine is a selective agonist at 5‐hydroxytryptamine receptors mediating vasodilation and tachycardia in anaesthetised cats
4. An analysis of the cardiovascular effects of 5‐hydroxytryptamine in conscious DOCA‐salt hypertensive rats
5. The mechanism of the hypotensive action of 5‐carboxamidotryptamine in conscious DOCA‐salt hypertensive rats
6. Sub‐types of neuronal 5‐hydroxytryptamine (5‐HT)receptors as identified by competitive antagonists
7. 3H]5‐hydroxytryptamine binding sites, presynaptic 5‐hydroxytryptamine autoreceptors in CNS and presynaptic 5‐hydroxytryptarnine receptors on sympathetic nerves
8. Further characterisation of pre‐ and postjunctional receptors for 5‐hydroxytryptamine in isolated vasculature
9. Tryptamine‐induced vasopressor responses in pithed rats are not predominantly mediated via 5‐hydroxytryptamine receptors
10. 5‐Hydroxytryptamine‐induced relaxation of isolated mammalian smooth muscle
11. 5‐Carboxamidotryptamine — a potent agonist at 5‐hydroxytryptamine receptors mediating relaxation
12. A comparison of 5‐hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein. Evidence for different receptor types using selective agonists and antagonists
13. Mechanism of the hypotensive effect of ketanserin
14. MDL 72222: a potent and highly selective antagonist at neuronal 5‐hydroxytryptamine receptors
15. Vascular reactivity to 5‐hydroxytryptamine and hypertension in the rat
16. Ketanserin — a novel antihypertensive drug?
17. Three distinct subtypes of serotonergic receptors mediate the triphasic blood pressure responses in rats
18. 2 receptors
19. Vascular responses to 5‐hydroxytryptamine in genetic and renal hypertensive rats
20. Vascular responses to serotonin in steroid hypertensive rats
21. Atriopeptins as cardiac hormones
22. Vagal sensory receptors and their reflex effects
23. The vascular action of natural serotonin, 5‐ and 7‐hydroxytryptamine and tryptamine
24. Mechanisms involved in the vasodilator action of 5‐hydroxytryptamine in the dog femoral arterial circulation in vivo
25. Permanent cannulation of aorta and vena cava in rats and ground squirrels
26. Pharmacological actions of sympathetic 5‐hydroxytryptamine (serotonin, thrombocytin)
27. Cardiovascular and respiratory response to intravenous serotonin in rats
28. 1 receptors
29. Cardiovascular and respiratory effects of β‐endorphin in anaesthetised and conscious rats
30. 5‐Hydroxytryptamine‐induced relaxation of neonatal porcine vena cava in vitro
31. 5‐Carboxamidotryptamine: A potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava
32. Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?